MedTrace Logo

The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction

NCT00611169 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-02-08

No results posted yet for this study

Summary

The purpose of this study to investigate whether the administration of high-dose tirofiban before primary PCI could reduce myocardial infarct size, using analysis of contrast-enhanced magnetic resonance imaging.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

tirofiban

tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Hyeon-Cheol Gwon, MD, PhD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-02-28
Completion
2007-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00611169 on ClinicalTrials.gov